Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "Where To Buy Sedatives"

Looking for quality documents?
external link icon
Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors
Development collaboration integrates Sartorius Stedim Biotech’s BIOSTAT® STR bioreactors and Repligen’s XCell™ ATF cell retention control technology Customers to benefit from simplified, scalable solutions for intensified cell culture GÖTTINGEN, Germany and WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) - Sartorius Stedim Biotech (SSB) (Euronext: DIM), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation (NASDAQ:RGEN), a global life sciences company focused on bioprocessing technologies, have entered into a collaboration agreement to integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT ® STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors. As a result of this collaboration, end users will stand to benefit from a single control system for 50 L to 2,000 L bioreactors used in perfusion cell culture applications. This single interface is designed to control cell growth, fluid
external link icon
Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
corporate icon
Universal Tubing Closures
Universal Tubing Closures can be used with all types of dialysis tubing to provide a leak-proof seal. These closures are required for use with Cellulose Ester (CE).
publications icon
Multi-attribute PAT for UF/DF of Proteins-Monitoring Concentration, particle sizes, and Buffer Exchange Publication
corporate icon
TangenX SC TFF Device
TangenX® SC TFF Device: Revolutionize tangential flow filtration processes   Eliminate the hassle and inefficiency that comes with traditional downstream filtration cassette formats. Say goodbye to cassette holders, complex setups, continued torquing, wasted time, and product loss risks. Discover TangenX® SC, the future of TFF cassette solutions for ultrafiltration and diafiltration, designed to meet the demands of today’s TFF processes while dramatically reducing setup time and minimizing product loss risk. 
external link icon
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
- Targeting ADC and Cell & Gene Therapy Customers - WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device. The technology is especially suited to the manufacture of biologics where fully closed systems are critical or ideal, including antibody drug conjugates (ADCs), viral vectors, nucleic acids and lipid nanoparticles, and can also be applied to monoclonal antibody, and recombinant protein production. TangenX SC is not only transformative, it is also a milestone achievement in the advancement of downstream flat sheet TFF technology for ultrafiltration and diafiltration (UF/DF), which is performed in nearly every biopharmaceutical manufacturing process to concentrate and purify drug. Christine Gebski, Senior Vice President, Filtration and
external link icon
Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer
corporate icon
Hollow Fiber Filters
Ideal for ultrafiltration and microfiltration of shear-sensitive modalities, Spectrum® Hollow Fiber Filters for TFF can accommodate the widest range of scales, membrane chemistries and pore sizes to maximize process outcomes.
external link icon
Repligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance for 2017
WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2016 financial results on Wednesday, February 22, 2017. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the reporting periods ended December 31, 2016. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 73917985. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 73917985.
external link icon
Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market
WALTHAM, Mass., March 26, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, today announced the commercial launch of its OPUS ® 45 cm diameter columns ("OPUS 45") with the largest capacity currently available on the market. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. OPUS technology increases facility flexibility, improves the speed of process development and reduces the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies. OPUS 45 was designed to process large single-use bioreactor harvests and will be formally launched at Biopharmaceutical Development & Production Week being held March 24-27 at the Hilton Bayfront Hotel in San Diego. "Since launching